×
About 688 results

ALLMedicine™ Ca 125 Center

Research & Reviews  222 results

Predictive value of preoperative inflammatory markers and serum CA 125 level for surgic...
https://doi.org/10.3233/CBM-201415
Cancer Biomarkers : Section A of Disease Markers; Sastra WIG, Aditya PPK et. al.

Nov 23rd, 2021 - It is essential in the management of ovarian cancers to identify the patients who will benefit from primary complete cytoreductive surgery and those who will rather benefit from neoadjuvant chemotherapy. To evaluate the predictive value of preoper...

Screening for Ovarian Cancer with CA 125 and Ultrasound Algorithm Does Not Reduce Morta...
https://www.ncbi.nlm.nih.gov/pubmed/34652113
American Family Physician; Ebell MH

Oct 16th, 2021 - Screening for Ovarian Cancer with CA 125 and Ultrasound Algorithm Does Not Reduce Mortality.|2021|Ebell MH,|

Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer
https://clinicaltrials.gov/ct2/show/NCT04377087

Sep 5th, 2021 - This is a Phase II trial will investigate if waiting until the time of chemical recurrence, denoted by rising CA125, to start a PARP inhibitor will lead to an improved time to next therapy with improved quality of life and at a lower financial tox...

Ovarian cancer surveillance in the clinical follow up of women with known BRCA1 or BRCA...
https://doi.org/10.1016/j.ygyno.2021.07.034
Gynecologic Oncology; Nañez A, Stram DA et. al.

Aug 1st, 2021 - To assess CA 125 and transvaginal ultrasound surveillance in women with BRCA1 or BRCA2 pathogenic variants in a pragmatic clinical setting with>1 year follow up. Retrospective cohort study in a large integrated health care system of women identifi...

see more →

Guidelines  1 results

Guideline No. 403: Initial Investigation and Management of Adnexal Masses.
https://doi.org/10.1016/j.jogc.2019.08.044
Journal of Obstetrics and Gynaecology Canada : JOGC = Jou... Salvador S, Scott S et. al.

Aug 2nd, 2020 - To aid primary care physicians, emergency medicine physicians, and gynaecologists in the initial investigation of adnexal masses, defined as lumps that appear near the uterus or in or around ovaries, fallopian tubes, or surrounding connective tiss...

see more →

Clinicaltrials.gov  16 results

Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer
https://clinicaltrials.gov/ct2/show/NCT04377087

Sep 5th, 2021 - This is a Phase II trial will investigate if waiting until the time of chemical recurrence, denoted by rising CA125, to start a PARP inhibitor will lead to an improved time to next therapy with improved quality of life and at a lower financial tox...

The Use of HE4 With Simple Ultrasound Rules to Predict Malignancy in a Pelvic Mass
https://clinicaltrials.gov/ct2/show/NCT03982914

Jun 11th, 2021 - Our objective is to determine if the combination of simple ultrasound features (IOTA simple rules) and a new biomarker (HE4) together with a common tumour marker (CA 125) can accurately predict ovarian cancer in women found to have a pelvic mass o...

Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer
https://clinicaltrials.gov/ct2/show/NCT04747717

Feb 11th, 2021 - The trial includes two arms, one of which is experimental arm with MP regimen chemotherapy that is compared with other arm with the standard TC regimen chemotherapy. To participate in this study, patients must have histologically confirmed epithel...

Ovarian Malignancy Incidence in Moderate Risk Women With Low CA 125
https://clinicaltrials.gov/ct2/show/NCT02247323

Feb 2nd, 2021 - About 10% of premenopausal women may have a surgery for ovarian masses. In premenopausal women the incidence of ovarian malignancy is 1:1000 in case of symptomatic ovarian cyst.1 CA125 is unreliable in differentiating benign from malignant ovarian...

CA125 and Ultrasound in Detecting Ovarian Cancer in Postmenopausal Women
https://clinicaltrials.gov/ct2/show/NCT00058032

Nov 19th, 2020 - OBJECTIVES: Determine the impact of preclinical detection of ovarian cancer by screening on ovarian cancer mortality in postmenopausal women. Determine the physical morbidity of ovarian cancer screening in this population. Determine the psychologi...

see more →

News  33 results

Expert Discusses Immunotherapy Across Gynecologic Malignancies
https://www.onclive.com/view/expert-discusses-immunotherapy-across-gynecologic-malignancies

Oct 6th, 2021 - Dmitriy Zamarin, MD, PhD Immunotherapy is slowly evolving in the gynecologic malignancies landscape and has moved beyond only having a role in ovarian cancer, according to Dmitriy Zamarin, MD, PhD. For example, pembrolizumab (Keytruda) has shown...

Maintenance Therapy for Recurrent Advanced Ovarian Cancer
https://www.onclive.com/view/maintenance-therapy-for-recurrent-advanced-ovarian-cancer

Apr 2nd, 2021 - Transcript: Bradley J. Monk, MD: So, most of the patients [who] we see in second line, who get a platinum doublet, [are] bevacizumab naïve because the FDA approval just happened in June 2018. So that means that patient, in the second line, is ...

Patient Selection: Adjuvant Therapy and Testing for ES NSCLC
https://www.onclive.com/view/patient-selection-adjuvant-therapy-and-testing-for-es-nsclc

Apr 2nd, 2021 - Benjamin P. Levy, MD: Who gets this, and for how long? Dr Leal, you’re not considering doing it yet, but let’s say you’ve decided that you’re going to give it routinely. Whom would you give it to, and for how long would you give the drug to them? ...

Multidisciplinary Approaches Are Needed in Ovarian Cancer
https://www.onclive.com/view/multidisciplinary-approaches-are-needed-in-ovarian-cancer

Dec 5th, 2020 - Nancy E. Davidson, MD Director University of Pittsburgh Cancer Institute, UMPC Cancer Center Pittsburgh, PA While ovarian cancer survival rates have improved slightly since the 1970s, the overall five-year survival for patients diag...

Tips for Talking With Patients: "Mother Question" and Sleep Test
https://www.onclive.com/view/tips-for-talking-with-patients-mother-question-and-sleep-test

Dec 5th, 2020 - Maurie Markman, MD Not surprisingly, as a longtime practicing oncologist specializing in gynecological cancer, I have noticed that certain themes and questions about individualized, scientifically unanswerable dilemmas often recur when I talk to ...

see more →

Patient Education  3 results see all →